DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 020236
The generic ingredient in SEREVENT is salmeterol xinafoate. There are eighteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the salmeterol xinafoate profile page.
Summary for 020236
Tradename: | SEREVENT |
Applicant: | Glaxosmithkline |
Ingredient: | salmeterol xinafoate |
Patents: | 0 |
Therapeutic Class: | Respiratory Tract Agents |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 020236
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | AEROSOL, METERED;INHALATION | Strength | EQ 0.021MG BASE/INH | ||||
Approval Date: | Feb 4, 1994 | TE: | RLD: | No |
Expired US Patents for NDA 020236
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline | SEREVENT | salmeterol xinafoate | AEROSOL, METERED;INHALATION | 020236-001 | Feb 4, 1994 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Glaxosmithkline | SEREVENT | salmeterol xinafoate | AEROSOL, METERED;INHALATION | 020236-001 | Feb 4, 1994 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Glaxosmithkline | SEREVENT | salmeterol xinafoate | AEROSOL, METERED;INHALATION | 020236-001 | Feb 4, 1994 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Glaxosmithkline | SEREVENT | salmeterol xinafoate | AEROSOL, METERED;INHALATION | 020236-001 | Feb 4, 1994 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Complete Access Available with Subscription